L
Lenoss Medical
Developing a natural and cement-free technology to treat spinal fractures
About Lenoss Medical
Lenoss Medical, founded in 2017 by Dom Messerli, is a biomedical device company concentrating on the physiological repair of osteoporotic spinal fractures. The firm is addressing the substantial market for vertebral compression fractures (VCFs), which has an estimated annual size of $600 million in the United States alone. The company's business model centers on selling its specialized medical instruments to healthcare facilities and has established purchasing agreements, including one with a hospital group in New York. Lenoss Medical operates as a private, venture capital-backed entity, having raised a total of $5.33 million. A seed round in May 2021 brought in $1.3 million, and a later Series A1 round in December 2023 secured $4 million to accelerate commercialization and expand clinical evidence.
The company's founder, President, and CEO, Dom Messerli, brings extensive experience from the spinal device industry. His background includes a 28-year career with over 20 successful product launches and leadership roles at DePuy Synthes, the orthopedic arm of Johnson & Johnson, where he was Director of R&D. This deep domain knowledge was pivotal in the conception of Lenoss Medical, which was guided by the philosophy that "ingenuity lies in simplicity". Messerli holds a Bachelor of Science in Mechanical Engineering from the University of Bern and an Executive MBA from Penn State University.
Lenoss Medical is targeting a critical deficiency in the standard treatment for VCFs, which often involves injecting liquid epoxy bone cement to stabilize fractures. This common procedure carries significant risks, including cement leakage into the bloodstream in approximately 23% of cases, which can lead to severe complications like embolisms and the need for open-heart surgery. Furthermore, the epoxy does not promote natural healing and can complicate future spinal surgeries.
In response to these challenges, Lenoss Medical developed the OsteoPearl VBA (Vertebral Body Augmentation) System. This system is a cement-free, minimally invasive technology that uses a 100% biological allograft implant made of cortical bone. The OsteoPearl implants are designed to create a three-dimensional structural matrix that provides immediate stability to the fractured vertebra. Crucially, they also possess both osteoconductive and osteoinductive properties, which create a scaffold for the patient's body to generate new bone and achieve long-term, natural healing. This approach avoids the risks of cement leakage and toxic fumes associated with traditional methods. The company has secured significant intellectual property, holding 23 granted patents for the OsteoPearl implant and its associated surgical instruments as of September 2025.
Source: Dealroom company dataNews
Open roles
Lenoss Medical in the Providence ecosystem
The Lenoss Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Beacon Angels
Slater Technology Fund
River Valley Investors- HWHansjoerg Wyss
- MFMagpie Neurosurgical Innovation Fund
Walnut Venture Associates- CACherrystone Angels
Series A7 investors entered at this stage
RightHill Ventures
Rouge Ventures
Vodia Capital
Xcellerant Ventures
Highpoint Ventures
Arizona Venture Development Corporation
Magpie MedTech Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lenoss Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lenoss Medical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

